Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

c-Met inhibitor MK2461

A selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. c-Met inhibitor MK2461 preferentially inhibits activated c-Met in an ATP-competitive manner, thereby inhibiting its tyrosine kinase activity, which may inhibit c-Met signaling and result in cell growth inhibition in tumors that overexpress c-Met. c-Met, encoding the hepatocyte growth factor receptor (HGFR) tyrosine kinase, plays an important role in tumor cell proliferation and has been shown to be overexpressed or mutated in a variety of cancers.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	MK2461

c-Met inhibitor MK2461

Search NCI's Drug Dictionary